In a surprising turn of events, the LGT Group Foundation has significantly reduced its holdings in Teladoc Health, Inc. The foundation sold off 41.3% of its shares during the first quarter of this year, shedding 18,708 shares and leaving them with a total of 26,600 shares in the renowned health services provider.
According to the recently submitted Form 13F filing with the Securities and Exchange Commission (SEC), LGT Group Foundation’s stake in Teladoc Health is now valued at $689,000. This unexpected move by one of the industry’s leading investment groups has garnered attention from analysts and investors alike.
Teladoc Health is widely recognized for its revolutionary virtual healthcare services offered both domestically and internationally. The company operates through two prominent segments – Integrated Care and BetterHelp. The Integrated Care segment provides various virtual medical services ranging from general medical support to expert medical advice, specialty medical consultations, chronic condition management, and mental health assistance.
Additionally, Teladoc Health offers enabling technologies and enterprise telehealth solutions catered specifically to hospitals and health systems. These solutions have proven instrumental in bridging gaps in healthcare accessibility across different communities.
Since this market development took place quite recently on July 3rd, various research analysts have provided their insights into the implications of LGT Group Foundation’s decision. Credit Suisse Group notably lowered their price target for Teladoc Health from $30.00 to $27.00 while maintaining a “neutral” rating on the stock. Canaccord Genuity Group also decreased their target price from $40.00 to $36.00 but upheld their “buy” recommendation for the company.
Another research report surfaced from StockNews.com on May 18th when they initiated coverage on Teladoc Health with a “sell” rating attached to it. However, it is important to note that these opinions differ among industry experts as 58.com reissued a “maintains” rating on the health services provider’s shares. Furthermore, Deutsche Bank Aktiengesellschaft boosted their target price from $27.00 to $29.00, signaling confidence in Teladoc Health.
In summary, LGT Group Foundation’s decision to decrease its holdings in Teladoc Health has sparked interest within the investment community. As analysts continue to evaluate and provide varying perspectives on the company’s future prospects, it is clear that Teladoc Health remains a significant player in the virtual healthcare industry. With its innovative solutions and commitment to enhancing access to healthcare services, Teladoc Health strives to meet the evolving needs of patients worldwide.
[bs_slider_forecast ticker=”TDOC”]
Institutional Investors Make Moves and Executives Sell: Shifting Landscape for Teladoc Health
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”TDOC” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]In the world of hedge funds and institutional investors, Teladoc Health has recently seen some significant changes to its position. Several hedge funds have made adjustments to their holdings in the technology-enabled healthcare company. One such example is Lindbrook Capital LLC, which raised its holdings in Teladoc Health by 11.6% during the fourth quarter of last year. This move saw Lindbrook Capital LLC’s ownership stake increase to 3,655 shares of the company’s stock, with a value of $86,000.
Another notable player in this shifting landscape is Forum Financial Management LP. In the first quarter of this year, the firm grew its position in Teladoc Health by 14.4%. Its ownership stake now stands at 3,094 shares worth $223,000. And it’s not just Forum Financial Management LP that has taken notice of Teladoc Health; Amalgamated Bank also increased its position in the health services provider by 1.3% during the fourth quarter. This move added an additional 392 shares to Amalgamated Bank’s portfolio, bringing their total ownership stake to 30,399 shares valued at $719,000.
Householder Group Estate & Retirement Specialist LLC also made moves in regards to Teladoc Health during the fourth quarter. The firm grew its position by 17.1%, acquiring an additional 448 shares worth $72,000. Finally, Oliver Lagore Vanvalin Investment Group increased its position by a staggering 94.3% during the third quarter of last year. This strategic move resulted in them owning 1,030 shares with a value of $26,000.
As these institutional investors make their mark on Teladoc Health’s stock price and market dynamics, it is worth noting that they collectively own a substantial portion of the company’s stock – specifically, about 81.81%.
While these changes within institutional investment are noteworthy, there have also been interesting developments among the company’s senior executives. The most recent news is that Senior Vice President Daniel Trencher sold 1,000 shares of Teladoc Health’s stock on April 17th. With an average price of $25.30 per share, this transaction resulted in a total value of $25,300. Currently, Trencher directly owns 24,520 shares, worth $620,356.
In addition to Trencher’s sale, insider Vidya Raman-Tangella also sold shares of Teladoc Health stock. On May 2nd, Raman-Tangella sold 15,372 shares at an average price of $26.76 per share – totaling $411,354.72. Following this transaction, she currently holds 25,620 shares worth $685,591.
It is important to note that these sales were disclosed through official legal filings and documents filed with the Securities & Exchange Commission (SEC). The detailed information regarding these transactions can be found on the SEC’s website.
Teladoc Health operates as a virtual healthcare services provider both in the United States and internationally. The company divides its operations into two segments: Integrated Care and BetterHelp segments. Through its Integrated Care segment, Teladoc Health offers various virtual medical services such as general medical consultations, expert medical advice across various specialties including chronic condition management and mental health support. Additionally, they provide enabling technologies for hospitals and health systems to integrate telehealth solutions into their operations.
On the financial front, Teladoc Health has seen some fluctuations in its stock performance recently. As of July 3rd this year (reference date), NYSE TDOC opened at a price of $25.32 per share. Over the past few months leading up to this date, the company had experienced a decline with its 50-day simple moving average closing at $24.78 while its 200-day simple moving average is slightly higher at $25.85. Teladoc Health’s stock price over the past year ranges from a low of $21.60 to a high of $44.66.
Looking at its quarterly earnings report, Teladoc Health last released its data on April 26th this year. The health services provider reported earnings per share of ($0.37) for the quarter, surpassing the consensus estimate of ($0.51) by $0.14. The company generated revenue amounting to $629.24 million in that period, exceeding analysts’ expectations of $617.55 million. However, it is important to note that Teladoc Health had a negative net margin of 285.51% and a negative return on equity of 5.81%. Analysts project that the company will post -1.38 earnings per share for the current fiscal year.
Overall, as institutional investors make strategic moves with their holdings in Teladoc Health, it will be interesting to see how these changes impact the company’s stock performance and market presence within the virtual healthcare sector.
